Skip to content Skip to site navigation Skip to local navigation
Department of Health

Medical Services Advisory Committee

  • MSAC
  • About MSAC
    • About MSAC
    • MSAC Process Framework
    • MSAC Executive Terms of Reference
    • MSAC Terms of Reference
    • MSAC Membership
    • ESC Terms of Reference
    • ESC Membership
    • PASC Terms of Reference
    • PASC Membership
    • Frequently Asked Questions
  • MSAC Meetings
    • Meetings
  • Public Funding
    • How to Apply for Public Funding
  • Forms Templates & Guidelines
    • Assessment Groups
    • Applicants
  • Guidelines Review
    • Guidelines Review
    • Guidelines Review Webinars
  • MSAC Applications
    • Application Page
  • Utilisation Monitoring Process
  • You are here:
  • Medical Services Advisory Committee /
  • MSAC Meetings /
  • Meetings /

ESC Meeting - 13 June 2019

Page last updated: 06 November 2019

Evaluation Sub-Committee - Applications Considered

  • 1196.2 - rTMS for the treatment of depression
  • 1342.5 - Oncotype DX
  • 1435.1 - Processing and cryopreservation (freezing) of ovarian tissue (complete or partial ovary removal)
  • 1510.1 - Emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with Haemophilia A
  • 1515 - Endoscopic placement and removal of an intra-gastric balloon for the management of overweight and obesity, in a high-risk patient group who have failed first line treatments
  • 1519.1 - Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive lymphoma
  • 1525 - LDR Brachytherapy for intermediate and high-risk prostate cancer
  • 1562 - Streamlining of MSAC assessment of positron emission tomography project
  • 1579 - Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with moderate to severe Haemophilia A (congenital Factor VIII deficiency) without Factor VIII inhibitors
  • 1589 - Prognostic value of the number of copies of the survival of motor neurone 2 gene for the severity of spinal muscular atrophy to determine eligibility for nusinersen in asymptomatic patients
Listen
  • MSAC Meetings
  • Meetings
  • Meetings
  • MSAC Email Bulletin


  • Feedback
Provide feedback

Comments will be used to improve web content and will not be responded to.

Real person check

This form uses a CAPTCHA to ensure that it is submitted by a person, instead of a machine or automated software.


Privacy statement

Your feedback has been submitted

Thank you for taking the time to provide feedback. It will be used to make improvements to this website.

Medical Services Advisory Committee

Medical Services Advisory Committee

© Commonwealth of Australia
ABN: 83 605 426 759

MBS Information

  • MBS Online
  • Legislation that covers the MBS
  • About MBS Factsheets
  • MBS Review

HTA Information

  • What is HTA
  • Australian Government HTA processes

Useful Links

  • MBS Online
  • PBS
  • PBAC
  • PLAC
  • Health Technology Reference Group
  • Healthier Medicare
  • MBS Review
  • TGA
  • HTA Conflict of Interest Guide

About

  • Copyright
  • Linking to this site
  • Accessibility
  • Disclaimer
  • Privacy
  • What is RSS?
  • Contact Us